Jennison Associates
VRNA

Jennison Associates’s Verona Pharma VRNA Stock Holding History

Jennison Associates’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-839,159
Closed -$79.4M – 655
2025
Q2 		$79.4M Sell
839,159
-421,994
-33% -$31.2M 0.05% 159
2025
Q1 		$80.1M Sell
1,261,153
-628,389
-33% -$37.6M 0.06% 151
2024
Q4 		$87.8M Buy
1,889,542
+148,656
+9% +$5.58M 0.05% 152
2024
Q3 		$50.1M Buy
1,740,886
+612,854
+54% +$15.1M 0.03% 229
2024
Q2 		$16.3M Sell
1,128,032
-465,801
-29% -$6.8M 0.01% 345
2024
Q1 		$25.6M Buy
1,593,833
+8,448
+0.5% +$146K 0.02% 317
2023
Q4 		$31.5M Buy
1,585,385
+142,819
+10% +$2.11M 0.02% 266
2023
Q3 		$23.5M Buy
1,442,566
+53,903
+4% +$1.04M 0.02% 292
2023
Q2 		$29.4M Buy
1,388,663
+359,665
+35% +$7.67M 0.02% 268
2023
Q1 		$20.7M Sell
1,028,998
-1,629
-0.2% -$35.2K 0.02% 324
2022
Q4 		$26.9M Buy
+1,030,627
New +$13.7M 0.03% 281

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jennison Associates's VRNA Position: Q3 2025 in Review

Jennison Associates sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 839,159 shares — an estimated $79.4M sold.

Jennison Associates first reported a position in VRNA in Q4 2022 and held it in 11 quarters. The position peaked at $87.8M in Q4 2024. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Jennison Associates reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Jennison Associates sold 839,159 Verona Pharma shares in Q3 2025, an estimated $79.4M.
  • Jennison Associates first reported a position in Verona Pharma in Q4 2022 and held it in 11 quarters.
  • Jennison Associates's Verona Pharma position peaked at $87.8M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Jennison Associates's 13F filing for Q3 2025, filed 30 Oct 2025.